MYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs Jun 10, 2021
Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of… May 18, 2021
Economic Burden Of Major Depressive Disorder Is $326.2 Billion Annually, According To New Study May 5, 2021
